Rare Disease Research Teams Receive Over $17m In Funding PDF Print E-mail
Thursday, 08 March 2012 09:08
The Canadian Institutes for Health Research (CIHR) has formed 9 new research teams that will focus on rare diseases. Funding from the CIHR will total $15.4 million over five years, primarily through the Institute of Genetics and the Institute of Nutrition, Metabolism, and Diabetes, while funding from partners will total an additional Total Partner Funding: $1.85 million, also over five years.

The overall objective is to transform fundamental biological research into medical practice and treatments in the area of rare diseases. For example, one team is conducting research on Fabry disease, a rare condition that affects many organ systems. This team will conduct a clinical research trial involving gene therapy, with the ultimate goal of establishing an effective treatment for this disease. The 9 collaborative research teams will investigate a range of issues related to rare diseases, including basic biological science, health services, and policies.

Project titles and funding amounts are as follows:
  • Developing a Canadian framework for evaluation and decision-making for expensive drugs for rare diseases through innovation, value, and priority setting. CIHR: $1,466,018
  • Developing Effective Policies for Managing Technologies for Rare Diseases. CIHR: $1,450,166
  • Emerging team in rare diseases: Achieving the "triple aim" for inborn errors of metabolism. CIHR: $1,490,492
  • Emerging Team: The Scleroderma Patient-centered Intervention Network. CIHR: $1,499,765
  • The FACTs Project: Fabry disease Clinical research and Therapeutics. CIHR: $2,450,000. Kidney Foundation of Canada: $50,000
  • New emerging team on Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): From models to treatment strategies. CIHR: $1,250,000. Ataxia of Charlevoix-Saguenay Foundation: $1,250,000
  • Chronic childhood vasculitis: Characterizing the individual rare diseases to improve patient outcomes. CIHR: $2,375,000. Canadian Organization for Rare Disorders: $125,000
  • Choroideremia: Expanding our understanding, exploring treatments. CIHR: $930,305. The Choroideremia Research Foundation Canada: $125,000. The Foundation Fighting Blindness: $300,000
  • Emerging Team to identify and characterize novel and existing Hereditary Spastic Paraplegia (HSP) disease genes. CIHR: $2,498,718

“CIHR is pleased to support these new research teams,” said Dr Lasko, scientific director of the CIHR Institute of Genetics. “This is the first time that Canada has supported interdisciplinary research of this kind, and marks a significant step forward in our country’s contribution to this field of study. It is our hope that this research will produce new practices, policies, and treatments that will transform the lives of Canadians living with rare diseases.”

“Canada has excellent researchers and we are delighted that they will now have the opportunity to focus on rare diseases,” said Dr Wong-Rieger, president of the Canadian Organization for Rare Disorders. “This CIHR research announcement will help ensure that Canada is contributing to improving the lives of not only Canadians, but all people living with rare disorders. The Canadian Organization for Rare Disorders is pleased to be a partner in supporting the research and a partner in some of the projects.”

A rare disease is one that affects a small number of people, when compared to the general population. In general, a disease is considered rare when it affects less than one in 2,000 people. They are often chronic diseases and life-threatening. For many rare diseases, signs may be observed at birth or in childhood, as in proximal spinal muscular atrophy, neurofibromatosis, osteogenesis imperfecta, chondrodysplasia or Rett syndrome. However, more than 50% of rare diseases only appear during adulthood, such as Huntington disease, Crohn’s disease, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, Kaposi’s sarcoma, or thyroid cancer.

Lad Product News (2012), "Research teams to probe rare diseases with $17M funding", LabCanada.com

 
More articles :

» Low-Dose Naltrexone for Pruritus in Systemic Sclerosis

Tracy Frech, Kirsten Novak, Monica P. Revelo, Maureen Murtaugh, Boaz Markewitz, Nathan Hatton, Mary Beth Scholand, Edward Frech, David Markewitz, and Allen D. SawitzkeReceived 31 May 2011; Accepted 14 July 2011Systemic sclerosis (SSc; scleroderma)...

» The World's First Successful Stem Cell Treatment of Autoimmune Diseases

The efficacy on intravenous infusion of adipose-derived mesenchymal stem cells was studied by researchers from five different countries—South Korea, United States, Japan, China, and Germany. These findings were reported in the Journal of...

» Treatment for Pulmonary Arterial Hypertension Cleared

has recently reported in its that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to...

» Jefferson Researchers Identify Mechanism Behind Fibrotic Disorder

Scientists from the of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for...

» What Is Barrett's Esophagus?

Barrett's is a precancerous condition in which the lining of the esophagus is replaced by abnormal cells, with the esophagus being that tube which connects the throat to the stomach. The esophagus is connected to the stomach by a muscular ring...

» New Site For Adult Stem Cell Resources Launched

A new website is detailing success stories in adult stem cell research. is part of a campaign to educate and spread awareness about the potentials and successes of adult stem cell therapies, and was created by the Family Research Council and...